Study Reaffirms Safety of Hepatitis B Vaccination at Birth Amid Shifting Federal Guidelines

A comprehensive review published in Pediatrics concludes that the hepatitis B virus (HBV) birth dose vaccine is safe and highly effective. These findings arrive at a pivotal moment, weeks after federal advisers voted to make newborn vaccination optional for infants born to hepatitis B–negative mothers.

The study examined decades of safety surveillance data, clinical trials, and epidemiological trends to evaluate the risk-benefit profile of the birth dose. Researchers found strong evidence supporting the vaccine's safety and no data favoring a delayed first dose. Notably, they found no serious adverse events attributable to neonatal vaccination and no basis for routine postvaccination serology testing. The review demonstrated that infant vaccination has driven a 99% reduction in pediatric HBV infections but identified potential public health consequences if a universal birth-dose policy were abandoned.¹

A Historic Policy Shift

On December 5, 2025, the Advisory Committee on Immunization Practices (ACIP) voted to allow shared clinical decision-making for infants born to hepatitis B–negative mothers, meaning parents and providers may now decide together whether to administer the birth dose or defer vaccination until 2 months of age. The CDC formally adopted the new recommendation on December 16, 2025. Infants born to hepatitis B–positive mothers or those of unknown status must still receive the vaccine within 12 hours of birth, along with hepatitis B immune globulin. The change represents the most substantial revision to HBV vaccination guidance in more than 30 years and has drawn strong pushback from infectious disease specialists, pediatricians, and hepatitis researchers.^2,3

Why the Birth Dose Matters

HBV is transmitted through blood and body fluids, and perinatal exposure during labor and delivery is among the most common transmission routes globally. Infants are uniquely vulnerable, as those infected in the first year of life have a 90% chance of developing chronic infection, and approximately 25% of those chronically infected will eventually die from liver failure or liver cancer. When the vaccine is given within 24 hours of birth, it is up to 90% effective in preventing perinatal transmission; completing the full series confers immunity in 98% of healthy infants, lasting at least 30 years. Starting the series at birth also reduces an individual’s lifetime risk of liver cancer by 84% and death from liver disease by 70%. The US had been on track to eliminate perinatal hepatitis B entirely, with only 13 reported cases in 2022; however, experts warn that progress could be reversed under the new guidance.^4,5

The Safety Record

A central concern driving the ACIP vote was whether older safety studies remain sufficient. The Pediatrics review addressed this directly, finding no increased risk of infant death, fever, sepsis, multiple sclerosis, autoimmune conditions, or autism spectrum disorder associated with neonatal vaccination. A separate CDC briefing document presented at ACIP’s September 2025 meeting similarly found that adverse events are rare and mild, primarily including transient local reactions or low-grade fever with no serious safety signals identified across multiple surveillance databases.^1,6

The Pharmacist’s Role

Pharmacists are uniquely positioned as vaccination guidance continues to evolve. Frequent, trusted contact with patients and caregivers in community settings creates opportunities to review vaccination histories, identify HBV risk factors, and counter the misinformation parents increasingly encounter on social media and through conflicting media coverage. With shared decision-making now embedded in ACIP guidance, pharmacists counseling new parents should be prepared to explain that the HBV birth dose has a robust safety record, that prenatal hepatitis B surface antigen testing fails to identify a meaningful proportion of infected mothers, and that deferring vaccination creates a window of vulnerability that cannot always be anticipated. Public health experts caution that when vaccines move from being universal to optional, vaccination rates frequently decline, and the decline is often permanent.^1,2,7

Reducing friction through same-day vaccination, accurate immunization documentation, and proactive follow-up on series completion is one of the most effective ways that pharmacists can protect this vulnerable population.⁷

REFERENCES

1. Ulrich AK, Fleming DF, Smith EA, et al. Hepatitis B vaccination at birth: safety, effectiveness, and public health benefit. Pediatrics. Published online February 5, 2026. doi:10.1542/peds.2025-075783

2. Fact sheet: hepatitis B immunization. CDC. December 16, 2025. Accessed March 3, 2026. cdc.gov/media/releases/2025/fact-sheet-hepatitis-b-immunization.html

3. CDC changes hepatitis B vaccine guidance for newborns—what parents should know. Bass Medical Group. December 5, 2025. Accessed March 3, 2026. bassmedicalgroup.com/blog-post/cdc-hepatitis-b-vaccine-newborn-guidance

4. Rosen A. Why hepatitis B vaccination begins at birth. Johns Hopkins Bloomberg School of Public Health. September 24, 2025. Accessed March 3, 2026. publichealth.jhu.edu/2025/why-hepatitis-b-vaccination-begins-at-birth

5. Fact checked: hepatitis B vaccine given to newborns reduces risk of chronic infection. American Academy of Pediatrics. June 25, 2025. Accessed March 3, 2026. aap.org/en/news-room/fact-checked

6. Su J. A review of the safety of hepatitis B birth dose vaccination. CDC. September 18, 2025. Accessed March 3, 2026. cdc.gov/acip/downloads/slides-2025-09-18-19/02-su-hep-b-508.pdf

7. McSweeney M, Antrim A. Hepatitis B vaccine safety, changing guidance, and the pharmacist's role. Pharmacy Times. January 5, 2026. Accessed March 3, 2026. pharmacytimes.com/view/hepatitis-d-vaccine-safety-changing-guidance-and-the-pharmacist-s-role